Sarepta Therapeutics (SRPT) Misses Q1 EPS by 24c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sarepta (SRPT) Bullish View Reiterated at Credit Suisse at EXONDYS51 Gains Momentum
April 28, 2017 6:45 AM EDTCredit Suisse analyst Alethia Young reiterated an Outperform rating and $64 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company raised guidance to $95M from $80M as the launch continues to look "highly encouraging"
The firm's new 2017 estimate is $103M, up... More
